C105. CIVIC CENTER: PULMONARY VASCULAR DISEASE最新文献_第2页

Evolving Metabolism Predicts Development of Pulmonary Arterial Hypertension in Systemic Sclerosis 进化代谢预测系统性硬化症肺动脉高压的发展

C105. CIVIC CENTER: PULMONARY VASCULAR DISEASE Pub Date : 2022-05-01 DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4918

C. Simpson, R. Harlan, A. Roux, S. Aja, D. Graham, A. Shah, L. Hummers, S. Mathai, P. Hassoun, R. Damico, PVDOMICS study group

引用次数: 0

Pulmonary Artery Calcification in Pulmonary Hypertension Due to Left Heart Disease 左心疾病所致肺动脉高压肺动脉钙化

C105. CIVIC CENTER: PULMONARY VASCULAR DISEASE Pub Date : 2022-05-01 DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4920

S. Liu, M. Kucherenko, P. Sang, Q. Li, J. Yao, I. Alesutan, J. Voelkl, C. Knosalla, W. Kuebler

引用次数: 0

Comparative Effectiveness of Inhaled Treprostinil vs Iloprost in Patients with Pulmonary Arterial Hypertension: An Analysis of U.S. Administrative Claims Data 吸入曲前列地尼与伊洛前列素对肺动脉高压患者的疗效比较:美国行政索赔数据分析

C105. CIVIC CENTER: PULMONARY VASCULAR DISEASE Pub Date : 2022-05-01 DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4912

C. Burger, B. Wu, P. Classi, K. Morland

引用次数: 0

Improved Survival for Systemic Sclerosis Associated Pulmonary Arterial Hypertension in the Last Decade 在过去十年中，系统性硬化症相关肺动脉高压患者的生存率有所提高

C105. CIVIC CENTER: PULMONARY VASCULAR DISEASE Pub Date : 2022-05-01 DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4915

H. J. Hassan, M. Naranjo, T. Housten Harris, A. Balasubramanian, C. Simpson, T. Kolb, R. Damico, S. Mathai, P. Hassoun

引用次数: 0

Characteristics of Patients Treated with Balloon Pulmonary Angioplasty at a High-Volume Pulmonary Thromboendarterectomy Center: Single Center USA Experience 在大容量肺血栓动脉内膜切除术中心行球囊肺血管成形术患者的特点:美国单中心经验

C105. CIVIC CENTER: PULMONARY VASCULAR DISEASE Pub Date : 2022-05-01 DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4911

J. Yang, D. Poch, M. Bautista, T. Fernandes, K. Kerr, D. Papamatheakis, V. Pretorius, M. Madani, M. Patel, E. Mahmud, N. Kim

{"title":"Characteristics of Patients Treated with Balloon Pulmonary Angioplasty at a High-Volume Pulmonary Thromboendarterectomy Center: Single Center USA Experience","authors":"J. Yang, D. Poch, M. Bautista, T. Fernandes, K. Kerr, D. Papamatheakis, V. Pretorius, M. Madani, M. Patel, E. Mahmud, N. Kim","doi":"10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4911","DOIUrl":"https://doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4911","url":null,"abstract":"Chronic thromboembolic pulmonary hypertension (CTEPH) is the result of incompletely resolved pulmonary emboli (PE) that lead to chronic right heart failure. The two mechanical treatment options are pulmonary thromboendar-terectomy (PTE) and balloon pulmonary angioplasty (BPA). There are no formal criteria for BPA patient selection and treatment decisions vary according to a center's experience with BPA and PTE. We performed a retrospective review of consecutive patients treated with PTE and BPA at UCSD from March 2015 to 2021. Clinical and hemodynamic data were collected. Patients were categorized according to the rationale for BPA. One hundred fifty three patients underwent 643 BPA sessions, and 1104 patients underwent PTE. Patients selected for PTE had worse baseline hemodynamics with mean pulmonary artery pressure 41.1 ± 11.7 versus 34.6 ± 11.2 mmHg, p < 0.001. 59% of patients selected for BPA had surgically inaccessible disease","PeriodicalId":286050,"journal":{"name":"C105. CIVIC CENTER: PULMONARY VASCULAR DISEASE","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114553607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0